Azapin

Quick links to important sections

Azapin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azapin

Property Description
Active ingredient Mirtazapine
Form Tablets, Oral disintegrating tablets
Pharmacological class Noradrenergic and specific serotonergic antidepressant (NaSSA)
Common purpose Modulates mood and provides a calming effect
Origin Synthetic, Tetracyclic compound

Azapin is a prescription-only medicine containing the active ingredient Mirtazapine, a synthetic compound broadly classified as an antidepressant. Its fundamental purpose is to modulate certain brain chemistry, helping to stabilize and elevate mood for patients dealing with affective disorders. Mirtazapine is recognized across clinical guidelines for its distinct pharmacological profile and efficacy in this general therapeutic area.

Unique Identity and Pharmacological Type

The drug belongs to a specialized group known as Noradrenergic and specific serotonergic antidepressants (NaSSAs), which distinguishes its function from other common classes. Structurally, Mirtazapine is defined as a tetracyclic compound and a Piperazinoazepine derivative. Azapin is classified as an atypical antidepressant due to its characteristic mechanism, which involves a dual action on neurotransmitter systems. It acts as an alpha2-adrenergic receptor antagonist to promote the release of both noradrenaline and serotonin—a feature that differentiates its action from selective reuptake inhibitors.

Furthermore, Mirtazapine is clinically recognized for its potent histamine H1 receptor antagonist properties. This means the medication inherently provides a general calming benefit that can be utilized alongside its mood-modulating effects. This single-active ingredient product is available as a peroral medication in several dosage forms, including traditional tablets and rapidly dissolving oral disintegrating tablets.

What side effects are possible with Azapin?

Azapin, an immunosuppressive antimetabolite, carries risks that warrant specific safety monitoring and precautions based on governmental regulatory warnings.

Adverse Reaction Scope

The most frequent adverse reactions are gastrointestinal (e.g., nausea, which is very common and dose-dependent) and hematologic (bone marrow suppression, leukopenia, thrombocytopenia). Very common adverse effects include bone marrow depression, leukopenia, and viral/fungal/bacterial infections (in transplant populations).

Serious Adverse Reactions

The drug carries a serious warning regarding the increased risk of malignancy, particularly non-Hodgkin's lymphoma (including the aggressive hepatosplenic T-cell lymphoma [HSTCL]) and skin cancers (melanoma and non-melanoma). Severe, life-threatening bone marrow suppression (myelotoxicity) is a dose-related risk. Other serious reactions include severe infections, pancreatitis, and potentially fatal hypersensitivity reactions.

Population-Specific Safety Considerations

Consideration Safety Restriction/Risk
Genetic Polymorphism Individuals with reduced or absent TPMT (Thiopurine S-methyltransferase) or NUDT15 activity are at a significantly increased risk of severe, life-threatening myelotoxicity.
Pregnancy Contraindicated for use in treating rheumatoid arthritis in pregnant women; may cause fetal harm. Effective contraception is required for both male and female patients.
Renal/Hepatic Impairment Dose reduction may be necessary due to slower clearance and increased risk of toxicity.
Prior Alkylating Agent Use Patients with rheumatoid arthritis previously treated with alkylating agents may have a prohibitive risk of malignancy if treated with Azapin.

Safety Monitoring

Regular complete blood counts (CBC), including platelet counts, are officially mandated during treatment, initially weekly, and then less frequently, to detect early signs of dose-dependent hematologic suppression.

Overdose and Emergency Response

Azapin (Mirtazapine) overdose is officially described in regulatory labeling as presenting with a range of central nervous system and cardiovascular manifestations. The most common signs documented include drowsiness, disorientation, impaired memory, confusion, and tachycardia.

Overdose carries the risk of severe and life-threatening outcomes. Post-marketing reports have identified the potential for severe cardiac effects such as QT prolongation, Torsades de Pointes, and ventricular arrhythmia, particularly when high dosages are ingested in mixed overdoses alongside other substances. Furthermore, severe neurological complications such as Serotonin Syndrome and seizures are documented risks associated with toxicity. These severe outcomes, including reported fatalities, necessitate immediate intervention.

If an overdose is suspected, official guidance mandates that an individual seek immediate medical attention. For symptoms such as collapse, seizure, breathing difficulty, or an inability to be awakened, emergency services must be contacted immediately. Management in the absence of a specific antidote is symptomatic and supportive, focusing on maintaining an adequate airway, oxygenation, and ventilation, along with continuous monitoring of cardiac rhythm and vital signs.

Therapeutic Uses of Azapin

What Azapin Treats: Main Uses and Benefits

Azapin (Mirtazapine) is commonly used across therapeutic domains where supportive symptom management is appropriate, particularly in conditions characterized by periods of heightened symptoms of affective disorders. It generally provides supportive therapeutic benefits across key areas that may impact patient comfort and daily stability. The medication is considered relevant for easing symptoms associated with Major Depressive Disorder, managing co-occurring insomnia, and supporting nutritional status in cases of appetite loss.

Relief for Depressive Symptoms and Sleep

This medication is generally used for managing and easing the overall symptom burden associated with Major Depressive Disorder (MDD), particularly in moderate to severe episodic or recurrent presentations. It assists with mood stabilization and offers symptomatic relief that may help patients cope more steadily with persistent feelings of low mood, emptiness, and emotional distress. It is commonly applied in clinical situations where low mood is accompanied by severe sleep architecture disturbances, such as difficulty initiating or maintaining sleep. This benefit may assist with supporting restful sleep and reduce chronic exhaustion.

“The medication is considered relevant when a patient’s emotional distress is accompanied by significant sleep and appetite challenges.”

Support for Appetite and Nutritional Status

The drug offers a supportive benefit for patients whose illness includes a pronounced loss of appetite (anorexia) and associated unintended weight loss. It is used to address this distressing manifestation, being applied in addressing appetite loss, which may contribute to general well-being and supports the patient's nutritional status.


Quick Fact: Relief for Co-Occurring Symptoms

Azapin is commonly used for managing depressed mood alongside significant insomnia and reduced appetite, providing supportive relief that addresses this unique cluster of symptoms.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Azapin (Mirtazapine) is defined by official regulatory criteria, specifying populations who are permitted, restricted, or strictly prohibited from use.

Contraindicated Populations

Azapin is absolutely contraindicated (must not be used) for two groups, as specified in regulatory labeling:

  • Patients with a known hypersensitivity to Mirtazapine or any excipient in the product.
  • Patients concurrently taking, or who have taken within the preceding 14 days, a Monoamine Oxidase Inhibitor (MAOI).

Age- and Condition-Based Restrictions

Eligibility is limited or restricted for several populations:

  • Pediatric Use: The drug is not recommended for children and adolescents under 18 years, as safety and effectiveness have not been established.
  • Organ Impairment: Caution is required in patients with moderate to severe renal impairment or hepatic impairment, as the clearance of Mirtazapine is reduced in these conditions.
  • Geriatric Use: Older adults may require special consideration due to the potential for reduced drug clearance.
  • Comorbidities: Caution is necessary for patients with a history of seizure disorder, mania or hypomania, or conditions such as angle-closure glaucoma.
  • Lactation: Mirtazapine is excreted into human milk, requiring a decision to discontinue the drug or discontinue nursing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Azapin (Mirtazapine) is defined by mandatory restrictions and documented pharmacokinetic and pharmacodynamic effects, strictly based on regulatory labeling.

Contraindicated Combinations and Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, is formally contraindicated. A 14-day separation period must be observed when switching between Azapin and an MAOI.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances (Examples) Documented Outcome
Metabolic (CYP) Induction Carbamazepine, Phenytoin, Rifampin Decreases Azapin plasma concentrations
Metabolic (CYP) Inhibition Ketoconazole, Cimetidine, Clarithromycin Increases Azapin plasma concentrations
Pharmacodynamic SSRIs, SNRIs, Triptans, St. John's wort Increased risk of Serotonin Syndrome
CNS Additive Effects Alcohol, Benzodiazepines, Sedatives Intensified central nervous system depression
Coagulation Status Warfarin Requires monitoring of the International Normalized Ratio (INR)

Population-Specific Considerations

Clearance is documented as being reduced in patients with hepatic impairment and moderate to severe renal impairment, which results in elevated Azapin plasma levels. Slower clearance is also noted in elderly patients.

Mechanism of Action

Dual Enhancement by Presynaptic Disinhibition

Azapin (Mirtazapine) is defined by pharmacological actions that modify central signaling, mediated by highly specific receptor blocking mechanisms rather than reuptake inhibition. The primary mechanism involves functioning as an antagonist at the presynaptic alpha2-adrenergic autoreceptor. This blockade removes the biological brake on neurotransmitter release, causing a simultaneous increase in the availability of both Noradrenaline and Serotonin (5-HT) in the synapse. This disinhibition mechanism initiates a cascade that results in a shift in central neurotransmitter levels, providing a defined modulation of central neuronal activity.

Targeted Serotonin Pathway Channeling

The molecule ensures signaling selectivity by blocking the undesirable postsynaptic 5-HT2 A, 5-HT2 C, and 5-HT3 receptors. This action forces the increased Serotonin to act only through the 5-HT1 A receptor pathway. This specific channeling process refines the neurotransmitter signal, leading to the modulation of central regulatory physiological responses.

Central Histamine Blockade

The molecule exerts a distinct physiological effect by functioning as an antagonist at the central Histamine H1 receptor. This high-affinity blockade interferes with the Histamine-driven pathways involved in arousal and alertness, resulting in a pronounced, rapid alteration of the CNS arousal state.

Dosage and Administration Information

How Azapin is Used: Official Administration Guidelines

Azapin (Mirtazapine) is administered exclusively via the oral route. Official regulatory guidelines establish the standard starting dose for adults at 15 mg once daily. This medication is typically taken preferably in the evening prior to sleep due to its established timing profile.


Dosing and Adjustment Rules

Administration frequency is once daily, and the dose should be adjusted slowly, with changes occurring only at intervals of one to two weeks or longer, and must not exceed the maximum recommended daily limit of 45 mg. Azapin can be taken with or without food.


Dosage Forms and Special Handling

The medicine is available as film-coated tablets and Oral Disintegrating Tablets (ODT). Standard tablets must be swallowed whole with fluid. The ODT form requires specific handling: it must be removed from the blister using dry hands, placed on the tongue to dissolve without chewing, and no water is required to swallow the dissolved material. Treatment discontinuation must always be performed gradually through dose tapering.


Population-Specific Instructions

Regulatory documents outline necessary dose adjustments for certain patient groups. A lower initial dose and slower titration may be appropriate for older adults, and dose reductions are also generally required for patients with moderate to severe hepatic or renal impairment due to altered drug clearance.

Recent Clinical Evidence

Research evidence / Overview of studies for Azapin (Mirtazapine)


Evidence for Use in Major Depressive Disorder (MDD)

This section summarizes the structure of the research base for Azapin, detailing the types of short-term randomized controlled trials (RCTs) and systematic reviews used in research exploring how symptoms change over time. The primary research consists of trials (typically 4 to 12 weeks) which compared Azapin against an inactive substance (placebo) or against active comparator drugs that were also studied for depression. These studies included Adults diagnosed with moderate to severe depression, focusing on conditions characterized by fluctuating manifestations.

Outcomes Measured in Acute MDD Trials

Research examined outcomes related to symptom intensity, specifically monitoring the change in participants' scores on standardized scales used to measure the severity of depression (such as the HAM-D or MADRS). Studies explored how symptoms evolved in the observed populations, tracking the percentage of people who had a reduction in their symptom scores (known as a "response") and those who met the criteria for minimal symptom scores (known as "remission" in clinical studies). Research also describes patterns related to the time interval until initial score modifications were observed.


Evidence for Managing Co-occurring Symptoms

This block describes the research that specifically focused on or tracked Azapin's effects on the outcomes related to systemic or functional imbalance often experienced by patients with depression, particularly disturbances in sleep and changes in appetite.

Studies Tracking Sleep Parameters

Azapin was evaluated in studies examining patient-reported outcomes describing perceived discomfort and concurrent sleep challenges. Findings describe patterns observed in the studies that include changes in sleep metrics, such as total sleep time and sleep onset latency. However, evidence derived from dedicated sleep studies, outside the research context of depression treatment, remains limited.

Studies Tracking Appetite and Nutritional Status

Research was conducted to observe changes in appetite and associated weight parameters. Studies documented patterns of score modification and measured change in body weight over the short term. These outcomes were often secondary to the main focus of the depression trials.


Key Limitations and Areas of Research Uncertainty

While extensive research exists for acute MDD treatment, the evidence quality varies across studies, and many of the early trials used short follow-up durations. Long-term effects are not fully established, particularly concerning the sustained impact on daily functioning or the prevention of recurrence over many years. Furthermore, results apply only to the populations studied, meaning data for certain groups, such as children or complex comorbidity populations, remain insufficient. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Azapin (FAQ)

Q: How quickly does Azapin start to have an effect?

Azapin generally reaches a stable concentration in the bloodstream (steady-state plasma concentration) within four to six days for most individuals. However, the full beneficial effects on mood may take several weeks to become noticeable. Official guidance suggests waiting one to two weeks before changing the dose to assess how the body is initially responding to the treatment.


Q: Is Azapin used for long-term or short-term treatment?

Clinical trials used to demonstrate Azapin's effectiveness were primarily short-term, typically lasting 6 to 8 weeks. While some individuals may continue treatment for longer periods, official controlled studies establishing effectiveness beyond a few months have not been systematically conducted. The duration of treatment is determined by the prescribing healthcare professional based on individual clinical assessment.


Q: Can I take Azapin if I am pregnant?

Official labeling states that there are no comprehensive, controlled studies of Azapin use in pregnant women. Therefore, the medication is generally considered for use during pregnancy only if the potential benefits are thought to clearly outweigh any potential risk to the fetus. Questions about use during pregnancy should be reviewed by a healthcare professional.


Q: What over-the-counter pain relievers can I take while on Azapin?

Specific over-the-counter pain relievers are not fully listed in official interaction documents. However, combining Azapin with medicines that significantly increase serotonin, such as triptans (sometimes used for migraine pain), can increase the risk of a condition called Serotonin Syndrome. As with all medications, any potential new over-the-counter products should be discussed with a healthcare professional.


Q: Does Azapin affect the way birth control works?

Regulatory information indicates that a component often found in oral contraceptives, ethinyl estradiol, may increase the concentration of Azapin in the blood. This means there could be a higher risk of side effects from Azapin itself. However, this documented interaction does not appear to involve a decrease in the effectiveness of the birth control medication.


Q: What is the difference between Azapin and similar-sounding medicine X?

Azapin belongs to a specialized class of drugs called Noradrenergic and specific serotonergic antidepressants (NaSSAs). Its mechanism is unique because it works by simultaneously blocking specific receptors to increase levels of both Noradrenaline and Serotonin. This action is distinct from that of other common types of antidepressants, such as the Selective Serotonin Reuptake Inhibitors (SSRIs).


Q: What age group is Azapin approved for?

Azapin is officially approved only for the treatment of Major Depressive Disorder in adults (those 18 years of age and older). Official studies have not established the safety or effectiveness of the drug in children and adolescents under 18 years of age.


Q: Is it okay to drink alcohol in moderation while taking Azapin?

Official documents state that the consumption of alcohol with Azapin is not recommended. Both alcohol and Azapin can intensify the depressant effects on the central nervous system (CNS), potentially leading to increased drowsiness, dizziness, and impairment of motor skills and judgment.


Q: How long after stopping Azapin will it be completely out of my system?

Azapin has a long half-life, meaning it takes a prolonged period for the body to eliminate the drug completely. Official warnings state that a minimum separation period of 14 days must be observed between stopping Azapin and starting a Monoamine Oxidase Inhibitor (MAOI) to allow for sufficient clearance and prevent a dangerous interaction.


Q: Can people with kidney problems take Azapin?

Regulatory documents indicate that patients with moderate or severe renal (kidney) impairment may require a lower dose. This is because reduced kidney function slows the clearance of Azapin, potentially increasing the concentration of the drug in the body and the risk of side effects.


Q: Can Azapin cause changes in weight?

Studies and official information indicate that Azapin can be associated with changes in appetite and weight. In clinical trials, a documented increase in appetite was reported in 17% of participants. Weight gain of 7% or more of baseline body weight was also reported in a small percentage of patients.


Q: Can Azapin be used by people who are breastfeeding?

The active ingredient in Azapin, Mirtazapine, is known to pass into human milk. Healthcare professionals must weigh the potential benefits of breastfeeding against the mother's clinical need for the drug and the potential risk of adverse effects to the breastfed infant before making a decision.


Q: Does Azapin affect blood sugar levels?

While not a primary effect, regulatory information indicates that Azapin can make it more challenging for individuals with diabetes to maintain consistent blood sugar control. Changes in blood sugar levels may be noted, and the prescribing healthcare professional may suggest increased monitoring for patients with diabetes.


Q: What is the difference in side effects between Azapin and its generic equivalent?

Regulatory bodies require that the generic version of the active ingredient (Mirtazapine) be biologically equivalent to Azapin. This means the clinical effect and overall safety profile should be comparable, including potential side effects.


Q: Are there any warnings about sunlight or UV exposure while taking Azapin?

The official product labeling for Azapin does not list photosensitivity (increased sensitivity to sunlight or UV light) as a frequently reported adverse reaction or specific warning.


Q: Are there any long-term effects associated with using Azapin?

The controlled studies establishing the drug's effectiveness primarily focused on acute treatment lasting 6 to 8 weeks. While many patients continue to take Azapin long-term, official regulatory documents indicate that the safety and effectiveness of using the drug for periods longer than a few months have not been systematically evaluated in long-term controlled trials.


Q: What are the signs of a severe allergic reaction to Azapin?

Official safety information notes that severe allergic reactions (hypersensitivity) are possible with Azapin. Signs to watch for include swelling of the face, lips, tongue, or throat, or the sudden onset of difficulty breathing. Such reactions are considered serious and should be addressed by a healthcare professional immediately.


Q: Do you need a special kind of prescription to get Azapin?

Azapin is classified as a prescription-only medicine. It is not scheduled under the Controlled Substances Act, meaning it does not typically require the special prescription forms associated with controlled drugs.


Q: Are there different strengths or formulations of Azapin?

Yes, Azapin is supplied in various strengths, including 7.5 mg, 15 mg, 30 mg, and 45 mg tablets. It is available in two formulations: film-coated tablets and orally disintegrating tablets (ODT), which dissolve on the tongue.


Q: Can Azapin cause stomach upset or nausea?

Official adverse reaction data shows that nausea is a commonly reported side effect in patients taking Azapin. Other frequent gastrointestinal side effects reported include dry mouth and constipation.


Q: Is it safe to drive or operate machinery while taking Azapin?

Because Azapin can cause somnolence (drowsiness) and impair judgment, engagement in activities that require mental alertness, such as driving or operating machinery, should be approached with caution, especially at the start of treatment.


Q: Can Azapin affect your mood or mental state?

The drug's primary purpose is to modulate mood, but it can, in rare cases, lead to the activation of mania or hypomania in susceptible individuals. Official warnings also highlight the potential for increased risk of suicidal thoughts and behaviors in young adults, particularly when treatment is started or the dose is changed.


Q: What should I do if the side effects of Azapin bother me?

The patient information leaflet typically suggests that severe or worsening side effects be communicated to the prescribing healthcare professional. Changes to the dosage or stopping the medication should only be done under the direction of a healthcare professional.


Q: Are there generic versions of Azapin available?

Yes, the active ingredient in Azapin, Mirtazapine, is widely available in officially approved generic versions in various strengths and dosage forms.


Q: Is Azapin a controlled substance?

No, Azapin (Mirtazapine) is not currently classified as a controlled substance under the regulatory framework of the Controlled Substances Act.


Q: Is Azapin considered a first-line treatment for the condition it treats?

While Azapin is effective and recognized in clinical guidance for its unique mechanism, other antidepressant classes, such as SSRIs, are generally recommended as initial or first-line therapy. Azapin is considered a clinically viable alternative.


Q: What conditions is Azapin not supposed to treat?

Azapin is officially approved only for treating Major Depressive Disorder (MDD) in adults. Regulatory approval does not extend to any other medical conditions, meaning its safety and efficacy for other uses have not been formally demonstrated in the official labeling.


Q: Does Azapin interact with high blood pressure medication?

Azapin carries a risk of causing orthostatic hypotension, which is a drop in blood pressure when changing position (like standing up). This risk may be heightened when the drug is taken alongside other medications, including those used to lower high blood pressure (antihypertensives).


Q: Why does Azapin sometimes have a bitter taste?

Official adverse reaction data documents that taste disturbance, which can include a metallic or bitter taste (dysgeusia), is a less common side effect associated with the medication. Additionally, the orally disintegrating tablet (ODT) formulation contains flavorings and sweeteners designed to help mask the drug's inherent taste.


Q: What should I do if I think Azapin is not working for me?

If concerns arise about the effectiveness of the medicine or if symptoms appear to be worsening, a review by the prescribing healthcare professional for guidance is indicated. Any decision to discontinue or adjust the dosage must be made in consultation with a healthcare professional.


Q: Why is Azapin sometimes prescribed when other drugs didn't work?

Azapin possesses a pharmacological profile distinct from other antidepressants, featuring a dual-action mechanism and potent central Histamine H1 receptor blockade. This unique way of modulating brain chemistry means it may offer benefits or a different response pathway for patients who did not respond adequately to a first-line antidepressant.


Q: Is Azapin approved in countries outside of the US?

Yes, the active ingredient in Azapin, Mirtazapine, is approved and commercially available in numerous international regions. This includes countries within Europe, the United Kingdom, Canada, and Australia, among others.


Q: Is Azapin the same drug as the one used ten years ago?

The fundamental active ingredient, Mirtazapine, remains the same chemical compound that has been available globally for many years. However, new generic versions, different formulations (like the ODT), and updated regulatory warnings regarding safety and potential risks have been approved and implemented over time.

How should Azapin be stored and disposed of?

How to Store and Dispose of Azapin?

This section outlines the official requirements for storing and discarding Azapin (Mirtazapine) as defined by regulatory documents.


Official Storage Requirements

Azapin tablets must be stored at room temperature, typically between 20 C and 25 C, and kept in their original container, which should be tightly closed. It is mandatory to store the medicine away from excessive heat, moisture, and direct light, and it must be kept from freezing.

For the oral disintegrating tablet (ODT) form, it must remain in the original blister packaging until the moment of use and cannot be stored once removed.

Child Safety: Keep this medicine out of the sight and reach of children.

Official Disposal Rules

Expired or unused Azapin must not be disposed of by throwing it away via wastewater or flushing it down the toilet. Disposal must be conducted in accordance with local pharmaceutical waste collection requirements, often utilizing official take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azapin found in:

A-Z Index: